CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Homepage / Programme Live / INHALE-1: a 26-week primary treatment with 26-week extension, open-label, randomized clinical trial evaluating the efficacy and safety of afrezza® vs rapid-acting analogue insulin in pediatric subjects with diabetes - (P-653)

INHALE-1: a 26-week primary treatment with 26-week extension, open-label, randomized clinical trial evaluating the efficacy and safety of afrezza® vs rapid-acting analogue insulin in pediatric subjects with diabetes - (P-653)

Talk details

ePosters on Display (no oral presentation)

New insulins

INHALE-1: a 26-week primary treatment with 26-week extension, open-label, randomized clinical trial evaluating the efficacy and safety of afrezza® vs rapid-acting analogue insulin in pediatric subjects with diabetes (P-653)

J. WOOD

Contact•Terms and Conditions•Powered by Key4Events

INHALE-1: a 26-week primary treatment with 26-week extension, open-label, randomized clinical trial evaluating the efficacy and safety of afrezza® vs rapid-acting analogue insulin in pediatric subjects with diabetes - (P-653)

Talk details

#{title}